Autism Spectrum Disorders Clinical Trials in Paris
2 recruitingParis, France
Showing 1–2 of 2 trials
Recruiting
Phase 3
Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
Autism Spectrum Disorders
Hospital General Universitario Gregorio Marañon103 enrolled5 locationsNCT07655115
Recruiting
Phase 2
Autism Spectrum Disorders: Double Blind Randomized Placebo-control Active Pilot Study of Transcranial Magnetic Stimulation Applied to the Superior Temporal Sulcus
Autism Spectrum Disorders
Assistance Publique - Hôpitaux de Paris20 enrolled1 locationNCT04442061